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ABSTRACT
Background: Breast cancer treatments in women with breast 
cancer often result in physical impairments that lead to activity 
limitations and participation restrictions. These limitations and 
restrictions manifest in impaired functional mobility skills that 
may impact survivorship. Thus, evaluation of functional mobil-
ity is an important part of survivorship care. Purpose: To iden-
tify functional mobility outcome measures that possess strong 
psychometric properties and are clinically useful for examination 
of women treated for breast cancer. Methods: Multiple elec-
tronic databases were searched for articles published after 1995. 
Studies were included if they reported psychometric properties, 
used clinically feasible methods, were performed on adults, and 
published in the English language. Each outcome measure was 
independently evaluated and rated by two reviewers. A single 
Cancer EDGE Task Force Outcome Measure Rating Form was 
completed for each category of functional mobility, and a recom-
mendation was made using the 4-point Cancer EDGE Task Force 
Rating Scale. Results: Of the original 819 articles found, 211 
were included in this review. A total of 11 measures are recom-
mended for clinical use: the Timed Up and Go; the 2-Minute, 
6-Minute, and 12-Minute Walk Tests; 10-Meter Walk; 5 Times Sit 
to Stand; Short Performance Physical Battery; Physical Battery 
for Patients with Cancer; Functional Independence Measure 
(FIM); Assessment of Life Habits; and Activity Measure for 
Post-acute Care. Conclusions: Many tools are available to assess 
upper extremity and overall functional mobility skills in women 
treated for breast cancer. There are currently no tools recom-
mended that assess community participation.
Key Words: breast neoplasms, outcome assessment, patient-
reported outcomes, psychometrics
INTRODUCTION
Breast cancer is the most common form of cancer in women 
in the United States with approximately 12% developing breast 
cancer in their lifetime.1 In 2015, an estimated 231,840 new cases 
of invasive breast cancer in women will be diagnosed, and in 2011 
an estimated 2,889,726 women were living with breast cancer.1 
There are approximately 3 million women diagnosed with breast 
cancer surviving today.1 For all stages of breast cancer combined, 
the 5-, 10-, and 15-year relative survival rates are 89%, 83%, 
and 78%, respectively.1 As the number of breast cancer survivors 
(BCS) continues to grow, many women will develop significant 
impairments of multiple body systems and functions.2
Functional mobility is an essential physical ability catego-
rized within the activities and participation domains of the 
International Classification of Functioning, Disability, and Health 
(ICF).3 Abilities related to changing and maintaining body posi-
tion including carrying, moving, and handling objects, and walk-
ing and moving, fall under the Mobility domain.3 The Self-Care 
domain contains abilities related to washing oneself, toileting, 
dressing, eating, and drinking, while the Domestic Life domain 
includes acquisition of necessities, household tasks, and caring 
for and assisting others.3 The categories of functional measures 
evaluated in this review fall under these specific subdomains of 
the ICF. Whether a BCS can safely move about, complete self-
care activities, and partake in domestic life must be assessed 
as part of the rehabilitation evaluation. Other measures used to 
detect and quantify impairments in functional mobility include 
additional upper extremity functional tests, tests for activities of 
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daily living, walk tests, and self-report questionnaires identifying 
impairments with community participation. Determining which 
measures of functional abilities are reliable and valid in this 
population provides a means for accurate and thorough assess-
ment of function.
Treatment for breast cancer is generally comprised of 
surgery and adjuvant strategies. Surgical interventions include 
removal of the tumor and surrounding tissue or mastectomy, 
which is the surgical removal of the breast. Treatments may also 
involve radiation therapy, chemotherapy that can be administered 
before or after surgery, targeted therapy, and/or hormone therapy 
such as selective estrogen receptor modifiers, aromatase inhibi-
tors, and ovarian ablation.1 The impact of cancer treatments on 
overall function has been explored in the literature, and find-
ings suggest that the cancer experience has a long-term negative 
influence on activity and participation abilities of survivors. 
Complications from cancer and its treatments may affect some 
patients’ functional mobility such as their ability to lift and carry 
objects, handle objects, complete self-care activities, and even 
walk and move about to carry out these daily activities.4-8 Nearly 
25% of cancer survivors report difficulty walking,9 reported 
more functional limitations than women without cancer,10 and 
generally scored lower on the Short Form-36 (SF-36), a patient-
reported measure that assesses health-related quality of life.11 In 
a study of cancer survivors post-treatment, the majority of whom 
were BCS, 22% had difficulty walking and 30% had participation 
restrictions.12 The Disabilities of the Arm, Shoulder, and Hand 
Questionnaire (DASH), a 30-item patient outcomes assessment 
designed to evaluate disorders of the upper limbs and monitor 
change or function over time, has been used to capture upper 
extremity dysfunction in women with or post breast cancer.13 
In survivors 6 months after diagnosis and treatment, 25.6% had 
a score greater than 20, where a higher score denotes greater 
disability. Scores greater than 20 indicate an impairment of motor 
function.13 At a 6-year follow-up, 21.1% had continued dysfunc-
tion with scores above 20.14 Certainly, researchers have estab-
lished that women with limitations in upper extremity range of 
motion and strength also report greater difficulties with activities 
of daily living (ADLs) and lower overall arm function on self-
reported questionnaires.14-16 Declines in activities and participa-
tion seen in this population often translate to changes in overall 
quality of life.
In 1991, the Task Force on Standards for Measurement in 
Physical Therapy (a committee of the American Physical Therapy 
Association [APTA]) established the criteria for valid, reliable, 
objective, and standardized tests and measures to assist clinicians 
in providing the highest quality of care.17 The criteria for appropri-
ate outcome measures needs to consider the following elements: 
(1) measurement of a domain within the ICF; (2) purpose of 
the measure relevant to obtaining discriminative, predictive, or 
evaluative information; (3) disease specific vs. general measure; 
self-report vs. performance-based measure; (4) patient’s ability 
and goals; (5) psychometric properties, particularly reliability, 
validity, diagnostic accuracy, minimal detectable change (MDC), 
and minimal clinical important difference (MCID); and (6) feasi-
bility, including the time, equipment, cost, space, and training 
required to administer and score the test results, overall burden on 
the patient to complete the test, and consideration of cultural and 
language barriers.18 The use of standardized outcome measures is 
an essential component of evidence-based practice and enhances 
the communication with patients and payers.19 The main barri-
ers to a standardization of physical therapy outcome measures 
include both the length of time and difficulty for patients to 
complete the test, as well as the time necessary for clinicians to 
administer the test and interpret the results.19
In 2010, the Oncology Section of the APTA created the 
Evaluation Database to Guide Effectiveness (EDGE) Task Force 
to critically review and recommend outcome measures to be 
used when assessing the status of cancer survivors.20 The Breast 
Cancer EDGE Task Force subcommittees have provided recom-
mendations for outcome measures in the areas of shoulder and 
upper quarter function,21,22 scapular assessment,23 strength and 
muscular endurance,24 pain,25 fatigue,26 balance and peripheral 
neuropathy,27 health-related quality of life,28 and cardiovascular 
fitness.29
This systematic review continues the ongoing efforts of the 
EDGE Task Force and evaluates the ways in which functional 
mobility is measured clinically in individuals with breast cancer. 
These tools provide important information about the patient, 
focus intervention strategies, and measure treatment effective-
ness, addressing the survivorship needs of women treated for 
breast cancer. The reliability, validity, MDC, and/or MCID are 
important psychometric properties that need to be established 
and assessed to justify the use of the selected outcome measures 
in the clinic.18 In addition, tools used to track and measure patient 
outcomes should be validated in the population in which they are 
used to be most beneficial for the patient. Lastly, these tools need 
to be considered in light of clinical utility, including the availabil-
ity of resources, cost, ease of use, and availability of normative 
data. The purpose of this systematic review is to make recom-
mendations of the best methods to evaluate functional mobility in 
BCS based on psychometric properties and clinical utility.
METHODS
Search Strategy
The authors systematically investigated the literature for 
outcome measures that directly measured functional mobility to 
evaluate the psychometric properties and clinical utility for use 
assessing BCS. The primary literature search took place during 
February and March of 2014 using 8 electronic databases: Google 
Scholar, Ovid, PubMed/Medline, CINAHL, Sports Discus, Web 
of Science, Cochrane Review, and PEDro. Search terms that were 
used included breast cancer or neoplasm in addition to multiple 
terms describing functional mobility including function, mobility, 
and limb use. The name of established functional tests were also 
specifically searched (refer to Appendix 1 for full list of search 
terms). Note that this list exceeds the number of functional tests 
investigated in this review. The final list includes only those 
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measures that were deemed to assess functional mobility skills, 
and that had published reports available for analysis. It is possible 
that outcome measures were omitted if the search did not reveal 
published information on the test.
Study Selection
To be included in this review, studies (1) were published 
in English; (2) performed tests of functional mobility; (3) 
reported psychometric properties; (4) presented clinically feasi-
ble methods; and (5) included adults (≥ 18 years), preferably 
women. Included articles were considered if published from 
1/1/1995-present. The breast cancer population took first priority 
within the search, however, if no studies included this population, 
women with other cancers, geriatric patients, and the general 
population were considered for review. 
Data Extraction
Teams of two reviewers independently performed data 
extraction using the Cancer EDGE Task Force Rating Form.20 
Tests of functional mobility were categorized into one of 4 group-
ings: (1) upper extremity functional tests, (2) ADL functional 
tests, (3) walk tests, and (4) self-report community participation 
tests. The categories for functional mobility were selected based 
on the qualities and foci of the functional outcome measures. 
Each functional category included a series of tests and assess-
ments. Refer to Appendix 2 for tests listed under each category. 
Following data extraction, reviewers independently appraised 
each outcome measure using all articles covering the outcome 
measure of interest. Outcome measures were rated 1-4 using the 
Cancer EDGE Task Force Rating Scale (Figure 1), taking into 
consideration both psychometric properties and clinical util-
ity. Outcome measures rated differently by each reviewer were 
discussed with 4 primary reviewers until consensus was obtained. 
RESULTS
The initial literature search for functional mobility testing in 
survivors of breast cancer resulted in 819 articles. The assessors 
reviewed all the titles and any duplicates were removed. A total 
of 297 articles were retrieved and assessed for eligibility. Abstract 
and article titles were then examined to identify studies that 
addressed the specific purpose of the research. After exclusions 
were applied, 211 articles were reviewed. See Figure 2 for flow 
diagram of literature search.
The number of articles reviewed for each category of tests 
were: (1) upper extremity functional tests—37, (2) ADL func-
tional tests—23, (3) walk tests—101, and (4) self-report commu-
nity participation tests—53. Some research studies evaluated 
multiple tools; therefore, the number of articles for each category 
is not mutually exclusive. Table 1 delineates the clinical useful-
ness of the recommended tests.
Eleven measures are recommended by the Breast Cancer 
EDGE Task Force members for use to measure the functional 
mobility skills of BCS in the clinic. These 11 measures are rated 
3 or 4 on the Task Force rating scale. Two measures are highly 
recommended (4) having been used in research with breast 
cancer: the 6-Minute Walk Test (6MWT) and the Timed Up and 
Go (TUG). Nine are recommended (3): 2-Minute and 12-Minute 
Walk, 10-Meter Walk, 5 Times Sit to Stand, Short Performance 
Physical Battery, Physical Battery for Patients with Cancer, 
Functional Independence Measure (FIM), Assessment of Life 
Habits, and Activity Measure for Post-acute Care. The Task Force 
is unable to recommend 10 measures due to lack of psychomet-
ric support or poor clinical utility. Two measures scored a 2A: 
Barthel Index and Reintegration in to Normal Living; 8 scored 
a 2B: Canadian Occupational Performance Measure, Impact on 
Participation and Autonomy Questionnaire, Life Satisfaction 
Questionnaire, Modified Rankin Scale, Timed 25 Foot Walk, 
Arm Mobility Ability Test, Wolf Motor Function Test, Action 
Research Arm Test. Finally, 4 measures are not recommended 
(1): Functional Status Examination, Participation Objective 
Participation Subjective, Participation Survey of Mobility 
Limited People, and 6-Minute Arm Test. See Tables 2 (recom-
mended outcome measures) and 3 (not recommended outcome 
measures) with Task Force ratings and clinical utility comments. 
Detailed psychometric properties of the recommended clinical 
measures of functional mobility testing in BCS can be found 
in Table 4 (supplemental online table provides detail for all 
reviewed outcome measures).
Discussion
The purpose of this review was to systematically identify 
and review methods of evaluating functional mobility in BCS 
and to make recommendations about these outcome measures 
based on psychometric properties and clinical utility. Since 
functional mobility comprises activities that enable an individual 
4 Highly Recommend Highly recommended; the outcome has good psychometric properties and good clinical utility. The measure has been used in research on individuals with or post breast cancer.
3 Recommend Recommended; the outcome measure has good psychometric properties and good clinical utility. No published evidence that the measure has been applied to research on individuals with or post breast cancer.
2A Unable to Recommend at this time
Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure. 
The measure has been used in research on individuals with or post breast cancer.
2B Unable to Recommend at this time
Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure. No 
published evidence that the measure has been applied to research on individuals with or post breast cancer.
1 Do Not Recommend Do not recommend; poor psychometrics &/or poor clinical utility (time, equipment, cost, etc.)
Figure 1.  Breast Cancer EDGE Task Force rating scale.
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Table 1.  Clinical Usefulness of Recommended Measures
Measure Equipment Needed Cost Ease of Use Scoring/ Interpretation
Normative 
Data
6-Minute Walk Yes – Stopwatch Free High Easy Yes
Timed Up & Go Yes – Stopwatch, chair,  
measuring tape
Free High Easy Yes
5 Times Sit to Stand Yes – Stopwatch, standard chair Free High Easy Yes*
2-Minute Walk Yes – Stopwatch Free High Easy Yes*
12-Minute Walk Yes – Stopwatch Free High – patient may be 
limited by condition
Easy Yes*
10-Meter Walk Yes - Stopwatch Free Medium – varied procedures Easy Yes*
Short Performance 
Physical Batter
Yes – Stopwatch, chair,  
measuring tape, cones
Free High Easy Yes*
Physical Battery for 
Patients with Cancer
No Free High - poor reliability for 
balance
Difficult Yes* 
Functional Independence 
Measure
Yes – varies based on category Moderate Low – training required Moderate Yes
Assessment of Life 
Habits
No Minimal High Difficult Yes*
Activity Measure for 
Post-acute Care
No Minimal Medium Moderate Yes*
*Not validated in breast cancer populations
Figure 2. Flow of literature search.
to move about in their environment in order to perform ADLs 
and participate in life situations,30 the measures reviewed by the 
Breast Cancer EDGE Task Force members span upper extremity 
functional tests, ADL tests, walk tests, and self-report community 
participation questionnaires. Eleven measures are rated 3 (recom-
mend) or 4 (highly recommend). 
The ability to complete functional mobility tasks is a neces-
sary part of the rehabilitation experience. Although the upper 
limb is the most obvious body part on which to focus, overall 
functional mobility of BCS should be included in assessment. It 
is for this reason that all levels of functional mobility were evalu-
ated in this review.
Upper Extremity Functional Tests
Of the upper extremity functional tests included in this 
review, only one, the Activity Measure for Post-Acute Care 
(AM-PAC), was recommended (rated 3). The AM-PAC assesses 
activity limitations based on the ICF model for patients across the 
post-acute care setting with varying diagnoses.31 The AM-PAC 
measures activity limitations in 3 distinct domains: basic mobil-
ity, daily activities, and applied cognitive; and it is available 
in two formats: a computer-based version and a short form 
version.32 The number of items varies depending on the format, 
as well as the setting (eg, in-patient vs. out-patient). The measure 
is very thorough and comprehensive, and has undergone substan-
tial psychometric testing and validation, but because the instru-
ment is meant to apply across many settings to as wide a patient 
population as possible, the specificity and sensitivity might be 
decreased. The AM-PAC was used in studies with other cancer 
diagnoses, but not specifically for BCS. There is a fee associated 
with use of the instrument and scoring is not intuitive. 
Activities of Daily Living Functional Tests
Two measures, the FIM and the Assessment of Life Habits 
(LIFE-H), were rated 3 (recommended). The FIM is a widely 
used uniform measurement system for evaluating basic quality 
of daily living activities in persons with a disability.33 The FIM 
is comprised of 18 items (13 motor tasks and 5 cognitive tasks) 
and assesses the amount of assistance an individual requires to 
complete the activities safely and effectively. Items include skills 
Rehabilitation Oncology
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related to self-care, sphincter control, transfers, locomotion, 
communication, and social cognition. The FIM was validated on 
a number of populations across a variety of settings with good 
psychometric properties.34-36 The FIM is a measure that physical 
therapists are familiar with, and the tool has been used in studies 
with a BCS cohort. However, there is a cost associated with use 
of the FIM, training/certification is required prior to using the 
FIM, and it ideally is scored by consensus with a multi-disci-
Table 2.  Recommended Outcome Measures
Measure Breast Cancer EDGE Task Force Rating Clinical Utility
6-Minute Walk 4 Good clinical utility, free and easy to administer. Evidence with BCS.
Timed Up and Go 4 Good clinical utility, free and easy to administer. Evidence with BCS.
5 times sit to stand 3 Good clinical utility, free and easy to administer, not used in BCS.
2-Minute Walk 3 Good clinical utility, free and easy to administer, not used in BCS.
12-Minute Walk 3 Free to administer but limited clinically with lower functioning individuals.
10-Meter Walk 3 Free and easy to administer, not used in BCS.
Short Performance Physical Battery 3 Free to administer. Not established in BCS.
Physical Battery for Patients with Cancer 3 Specific to the cancer population. May not have time to use in the clinic.
Functional Independence Measure 3 Cost to purchase. 30-40 minutes to complete. Not valid in cancer population.
Assessment of Life Habits 3 Takes time to complete with challenging scoring. Lower clinical utility.
Activity Measure for Post-Acute Care 3 CAT version available. Based on WHO ICF. Not used in BCS.
Abbreviations: BCS, breast cancer survivors; WHO, World Health Organization; ICF, International Classification of Functioning; CAT, computer assisted testing
Table 3.  Outcomes Measures Not Recommended 
Measure Breast Cancer EDGE Task Force Rating Clinical Utility
Barthel Index 2A Not used in the cancer population.
Reintegration into Normal Living/Life 
Index 2A 10 minutes to complete, insufficient information to recommend at this time.
Canadian Occupational Performance 
Measure 2B Fee to use. No evidence in use in BCS.
Impact on Participation and Autonomy 
Questionnaire 2B 30 minutes to complete, not used in cancer population.
Life Satisfaction Questionnaire 2B 10-30 minutes to complete, free, not used in cancer populations. 
Modified Rankin Scale 2B 6-30 minutes to complete. Free to complete. Experience raters needed to decrease bias.
Timed 25 Foot Walk 2B Easy to administer. Not validated in cancer population.
Arm Mobility Ability Test 2B Lengthy time to complete and scoring is difficult. No evidence in BCS.
Wolf Motor Function Test 2B Used in the neurological population but not used in BCS.
Action Research Arm Test 2B Uses multiple pieces of equipment. Used in the neurological population but not used in BCS.
Functional Status Exam 1 6-30 minutes to complete. Used in the neurological population. 
Participation Objective, Participation 
Subjective 1 6-30 minutes to complete. Not recommended, no evidence in cancer populations.
Participation Survey of Mobility Limited 
People 1
20-40 minutes to complete online or 60-90 minutes hard copy – lack of clinical 
feasibility.
6-Minute Arm Test 1 Used to assess cardiovascular fitness. No psychometric data and difficulty obtaining the equipment.
Hi-Level Mobility Assessment Tool 1 Developed specifically for high level traumatic brain injury.
Abbreviation: BCS, breast cancer survivor
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Table 4.  Psychometric Properties of Recommended Outcome Measures
Measure Intra-rater Reliability 
Inter-rater 
Reliability
Test/Re-test 
Reliability
Responsiveness to 
Change Validity
Upper Extremity Functional Tests
Activity Measure 
for Post-acute Care
(not tested in cancer 
population)
Daily Activity:
ICC = 0.9063
Mobility:
ICC = 0.8663
Applied cognition:
ICC = 0.6863
Daily Activity:
ICC = 0.9663
Mobility:
ICC = 0.9763
Applied cognition:
ICC = 0.9163
MDC 
AMPAC Computer version64 
basic mobility =4.28 points
Daily activity = 3.7 points
Applied cognitive = 5.55
MDC 
AMPAC CAT = 2 points 65
With SF-36: r = .8466
With Gait speed: r = 6566
With 6MWT: r = 0.6766
Internal consistency 
Cronbach alpha
 Total: 0.92-0.9467 
 Specific dx groups: 0.90-0.9567
Activities of Daily Living Functional Tests
Functional 
Independence 
Measure (FIM)
(not tested in cancer 
population)
ICC = 0.9568 ICC = 0.80 - 
0.9069,70
With Barthel Index r = 0.92-0.9471
Assessment of Life 
Habits (LIFE-H)
(not tested in cancer 
population)
ICC = 0.8972 ICC = 0.74 - 
0.8937,73,74 
With Craig Handicap Assessment and 
Reporting Technique:  r = 0.14 - 0.7675
With Community Integration 
Questionnaire: r = 0.54 - 0.7575
Internal Consistency:
Cronbach alpha =  0.82 - 0.9075 
Walk Tests
2-minute walk test
(not tested in cancer 
populations)
ICC = 0.83 – 
0.98076-80
Coefficient of 
variation: 
r = .04981
ICC = 0.85 - 
0.9778,79,82
ICC = 0.94 - 0.9582   SEM estimated ≤ 6.3m83
MDC (older adults):
13.4 - 14 m79,82
With TUG:  r = -0.68 - 0.8782,83
With BBS: r = 0.8882
With 6MWT: r = 0.93 – 0.9682,84
With EDSS: r = -0.6184
With MSWS-12:   r = -0.7284
With MFIS physical sub-index: r = 0.3184
6-minute walk test Other populations
ICC =  0.74 - 
0.9941,85
Other populations:
ICC = 0.78 - 
0.9941,85  
 Cancer population:
ICC: 0.93 (0.86-
0.97)40
Other populations:
ICC = 0.94-
0.9944,86-92
R = 0.953  
Cancer population:
  Coefficient of repeatability:  
60m40
Small meaningful change: 
20m93
Substantial meaningful 
change:
 50m93
Cancer population:
With:40
 exercise capacity r = 0.67      maxi-
mum workload  r = 0.70, 
 perceived physical function  r = 0.55 
age r = -0.52
Other populations:
With 10MWT:   r = -.9592,94 
With TUG: r = -0.8890,94,95
With Walking Index for SCI: r = 0.6094
With 2MWT: r = 0.99785
12MWT: r = 0.99485
10m fast gait: r = 0.9490
10m comfortable gait: r = 0.8490
12-minute walk test
(not tested in cancer 
populations)
 ICC= 0.7187 ICC = 0.6887 Standardized response mean 
(SRM) score = 1.9087 
10-meter walk
(not tested in cancer 
populations)
ICC = 0.9841,95 ICC = 0.97 - 
0.9941,95,96
R = 0.75-0.9097
ICC = 0.82 - 
0.9356,66,90,98-100
MDC
.013 - 0.25m/s89,95,101,102
 
With dependence in self-care: 
 r = 0.60 - .087102
With dependence in mobility:
 r = 0.34- .074102
With dependence in domestic life:
 r = 0.34 - 0.74102
With instrumental activities of daily 
living: r = 0.76103 
With Barthel Index: r = 0.78103 
With TUG: ICC = -0.84 to -0.9190
With 6MWT: ICC = 0.89 – 0.9590
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Table 4 Continued.
Measure Intra-rater 
Reliability 
Inter-rater 
Reliability 
Test/Re-test 
Reliability 
Responsiveness to 
Change
Validity
Walk Tests – continued
Timed Up & Go 
(Cognitive & 
Manual)
r = 0.90104 MCID = 1 sec105 Cancer population:
With falls within 1 year: r = 0.85106
With falls within 3 months: r = 0.85106
With falls since cancer diagnosis:        
r = 0.74106
With Simmonds Performance Status 
Battery: r = 0.85106
Other populations:
With 5 times sit to stand: r = 0.60104
With standing balance: r = -0.31104
With Rapid Disability Rating Scale:
 r = 0.42104
With S-36 physical function: r = -0.50104
With 2MWT:  r = 0.68 - 0.81107
5 Times Sit to Stand
(not tested in cancer 
populations)
ICC=0.9999-101 r= 0.82 – 0.9999-105 MDC 2.5 – 4.2sec101,102,106
MCID ≥ 2.3 sec107
With PASE: r = -0.3899
With PDQ-mobility: r = 0.5899
With ABC: r = 0.54 – 0.6899,107
With Mini-BEST: r = 0.7199
With quads MVIC:  r = -0.33 – 0.6599,108
With 6MWT: r = 0.60 – 0.7599,108
With 5MWT: r = -0.78100
50 foot walk: r = 0.87100
Repeated trunk flexion: r = 0.64100
With DGI: r = -0.58107
Short Performance 
Physical Battery 
(SPPB)
(not tested in cancer 
populations)
ICC >0.90118 ICC >0.90118 ICC = 0.82 – 
0.92118-121
MDC
1.42 – 2.9 points (elderly)66,93
3.42 points (s/p hip frac-
ture)122
With self-reported mobility = 89%59
With ADL associated disability = 96%59
Physical Perfor-
mance Battery 
for Patients with 
Cancer
r = 0.98 and 0.99106 r = 0.69-0.99106 Cancer pop:
Portions correlated with TUG:106
 Walk test: r = 0.85
 Sit to stand: r = 0.74
 Sock test: r = 0.55
 6MWT: r = -0.62
Portions correlated with functional 
status:88
 ADLs: r = 0.39 – 0.43
 Forward reach: r = 0.25
  Sit to stand: r = 0.44
 6MWT: r = -0.49
Abbreviations: ICC, intraclass correlation coefficient; r, Pearson’s Coefficient Correlation; SEM, standard error of measurement; MDC, minimal detectable change; MCID, minimal clinical 
important difference; BCS, breast cancer survivors; QOL, quality of life; 2MWT, 2-minute walk test; 6MWT, 6-minute walk test; BBS, Berg Balance Scale; EDSS, Expanded Disability Status 
Scale; MSWS, Multiple Sclerosis Walking Scale; TUG, Timed Up and Go; MFIS, Modified Fatigue Impact Scale; AM-PAC, Activity Measure for Post-acute Care; CAT, Computer Adaptive 
Testing; SF-36, Short Form-36
plinary team. The test may take up to 45 minutes to administer/
complete, which can affect its clinical utility.
The LIFE-H assesses the quality of an individual’s social 
participation based on one’s perception of difficulty experienced 
and how much assistance is required to complete a task.37 The 
long and short form of the instrument (ver. 3.0) has 240 and 69 
items, respectively, covering 12 domains including nutrition, 
personal care, mobility, interpersonal relationships, community 
life, and recreation. The LIFE-H is comprehensive and has good 
psychometric properties, however, Magasi and colleagues38 point 
out that the LIFE-H was not widely used outside of the group 
that developed the instrument, and the conceptual foundation on 
which the instrument was grounded was not widely known, limit-
ing its adoption by the clinicians and researchers. The LIFE-H 
was not validated in the cancer population. Moreover, scoring 
of the instrument is difficult, and it may take an hour or more to 
complete the instrument (up to 60 minutes for the short form, up 
to 120 minutes for the long form). 
Walk Tests
Walk tests fall under the ICF Mobility Domain. The ability 
to safely and efficiently walk and move about is considered an 
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essential life skill. The following tests were rated a 3 (recom-
mended) or 4 (highly recommended) by the EDGE Task Force.
The 6MWT and the TUG were rated 4 (highly recom-
mended). Both of these tests exhibit good psychometric prop-
erties, and were tested and used extensively with BCS. In the 
6MWT, the individual is asked to walk as far as possible for a 
total of 6 minutes on a hard, flat surface; the patient is allowed to 
self-pace or rest as needed during the test.39 This test was origi-
nally developed as a measure of exercise tolerance in patients 
with chronic respiratory disease and heart failure, but has since 
been used as a performance-based measure of functional capacity 
in many other populations.40-44 Among patients with cancer, the 
6MWT exhibited good reliability, and the distance walked corre-
lates well to exercise capacity and workload.40 The 6MWT has 
been used to assess physical impairments following breast cancer 
treatment,45 as well as functional improvements after exercise 
programs for BCS.46-48
The second highly recommended test, the TUG, measures the 
time in seconds for a person to rise from sitting in a standard chair 
with arms, walk 3 meters, turn, walk back to the chair, and sit 
down.49 Thus, this test provides an overall assessment of elements 
that are important for independent mobility including sit to stand 
to sit transfers, ambulation, and turning about in space. The TUG 
has good inter/intrarater reliability and is highly correlated with 
gait speed,50 which in turn, is a significant predictor of functional 
dependency and disability.51,52 Among patients with cancer, the 
TUG was used as a measure of performance status, mobility, and 
postural control.51,53 Both the 6MWT and the TUG are free and 
easy to administer, requiring little to no equipment. The instruc-
tions for both tests are also available in many languages. 
Six measures in the Walk Test category are rated recom-
mended (rated 3). These tests include the 2-minute and 12-minute 
walk, 10-meter walk, as well as physical performance batteries 
that incorporated walk tests:  Short Performance Physical Battery 
(SPPB), and the Physical Performance Battery for Patients with 
Cancer. The 5 times sit-to-stand test (FTSST or 5xSST) was 
also included in this category. The 2- and 12-minute walk tests 
(2MWT, 12MWT) are both variants of the 6MWT. The individu-
als walk as far as they can in 2 or 12 minutes, respectively. Like 
the 6MWT, individuals can rest or stop as needed, and use their 
customary walking aid. The 2MWT was proposed as an alterna-
tive to the 6MWT as being more clinically feasible for a patient 
with significant muscle weakness, gait inefficiency, or fatigue.54 
On the other hand, the 12MWT was proposed in response to the 
observation that patients tend to walk at a faster pace initially 
before settling to a more constant speed, thus a longer walk test 
would be a more accurate measure of functional capacity and 
exercise tolerance.55 While both of these measures were tested 
in other populations and exhibit good clinical utility, the 2MWT 
has not been used, to our knowledge, on BCS. The 12MWT may 
have limited utility with BCS as the patients who have significant 
sequelae from breast cancer treatment (eg, peripheral neuropathy, 
cancer-related fatigue, etc) might have difficulty completing the 
test due to the longer time frame. The 10-meter walk (10MWT) 
assesses the time it takes an individual to walk 10 meters. The 
distance is then divided by the time to complete that distance in 
order to derive gait speed. There are variations of this measure in 
which the individual walks at his/her preferred or fastest speed 
possible.56 While this test is easy to administer, there are different 
reported methods for how to conduct the 10MWT, such as the use 
of extra distances to allow the individual to accelerate or deceler-
ate.57 Moreover, there is limited information on its use with BCS. 
The SPPB and Physical Performance Battery for Patients 
with Cancer are both physical performance batteries. Each of 
these batteries attempts to capture a hierarchy of function for a 
variety of physical tasks that mimic daily activities. The SPPB 
captures mainly lower extremity function, while the Physical 
Performance Battery for Patients with Cancer also includes upper 
extremity tasks. The SPPB is composed of a balance task, a short 
walk at the usual speed, and 5 repetitive chair stands.58 This test 
was designed such that it could be performed in almost all clini-
cal and research settings, and to quantify physical performance 
changes over time.59 The SPPB captures domains of strength, 
endurance, and balance, is relatively easy to administer, and was 
used extensively in studies in the older population. However, its 
use with BCS is limited, perhaps because lower extremity func-
tion is not perceived as an area of immediate concern compared 
to upper extremity function. Of note, Curb and colleagues60 report 
that the balance subscale of the SPPB has poor reliability, and 
suggests using the summary SPPB score or a difference balance 
assessment tool if balance is the construct of interest.
The Physical Performance Battery for Patients with Cancer 
was devised specifically for the oncology population.61 This 
test battery has 9 separate individual tests. While the individual 
tests are relatively easy to administer/perform, the total time to 
complete the test battery may be up to 40 minutes. The Physical 
Performance Battery for Patients with Cancer was used in studies 
including BCS, however, the time it takes to complete the test 
battery as well as putting the results into context (ie, results of the 
battery vs. individual tests) may diminish its clinical usefulness. 
The 5xSST assesses lower extremity strength and ability to 
perform transitional movements. Individuals are asked to stand up 
from a standard chair and sit down 5 times, as quickly as possible, 
while keeping arms folded across the chest.62 The 5xSST is quick 
and easy to administer and is a test within the SPPB. The 2 Times 
Sit to Stand is a test within the Physical Performance Battery for 
Patients with Cancer. There are other versions that were reported, 
such as a 30-second sit to stand, a 10 times sit to stand, and a 
single leg sit to stand. However, the 5xSST and other versions 
were not specifically tested in the cancer population. 
Self-report Questionnaires/Community Participation
None of the reviewed scales for self-report and community 
participation are recommended by this Task Force. They either 
lacked psychometric testing or clinical utility presenting issues 
for the clinician as the dearth of quality scales leaves a void 
in accurate assessment. One might argue that some assessment 
is better than no assessment; however, should the assessment 
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Appendix 1. Search Terms
Primary search terms: breast cancer, neoplasm, function, functional mobility, limb use
Secondary search terms:
Appendix 2.  Categories of Functional Mobility Testing and Respective Tests
Upper Extremity 
Functional Movement 
Tests
ADL Functional Tests 
Category (Physical and  
Self-report)
Walk Tests Self-report Community Participation
•   Action Research Arm Test
•   Activity Measure for Post-acute 
Care
•   Arm Motor Ability Test
•   Six Minute Arm Test (6-MAT)
•   Wolf Motor Function Scale
•   Assessment of Life Habits
•   Action Research Arm Test
•   Activity Measure for Post-acute 
Care
•   Arm Motor Ability Test
•   Canadian Occupational 
Performance Measure
•   Barthel Index
•   Functional Independence 
Measure/Functional Self-
assessment
•   2 Minute Walk Test
•   6 Minute Walk Test
•   12 Minute Walk Test
•   10 Meter Walk Test
•   5 Times Sit to Stand
•   Timed 25 Foot Walk
•   Timed Up & Go (Cognitive and 
Manual)
•   High-Level Mobility Assessment 
Tool (HiMAT)
•   Short Performance Physical Battery
•   Physical Performance Battery for 
Patients with Cancer
•   Impact on Participation and Autonomy 
Questionnaire (IPAQ)
•   Life Satisfaction Questionnaire (LSAT-9)
•   Functional Status Examination
•   Modified Rankin Scale
•   Participation Measure for Post-acute Care
•   Participation Objective
•   Participation Subjective (POPS)
•   Participation Survey of Mobility Limited 
People (PSM)
•   Reintegration to Normal Living/Life Index
Abbreviation: ADL, activities of daily living
be unreliable or lack validity, then it may not assess the given 
construct accurately. Because the Task Force cannot recommend 
any of the measures for self-report and community participation, 
using traditional descriptive techniques to define performance is 
recommended.
CONCLUSION
Assessing functional mobility is an important part of breast 
cancer survivorship. Many tools exist that accurately and reliably 
assess upper extremity functional mobility, activities of daily 
living, walking, and community participation. Eleven measures 
are recommended for use by the Oncology EDGE Task Force. 
Tools that assess community functional mobility currently lack 
either psychometric validation or clinical utility, or both. Further 
research exploring community functional mobility for this popu-
lation is necessary either to develop further existing tools or 
design new tools that possess both sound psychometric properties 
and good clinical utility. Survivorship care for women treated for 
breast cancer is enhanced by using the recommended measures.
•  5 Times Sit to Stand
•  10 Meter Walk Test
•  2 Minute Walk Test
•  6 Minute Walk Test
•  12 Minute Walk Test
•  Action Research Arm Test
•  Activity Measure for Post-acute Care
•  Arm Motor Ability Test
•  Assessment of Life Habits
•  Barthel Index
•  Canadian Occupational Performance Measure
•  Clinical Test of Sensory Interaction and Balance
•  Community Balance and Mobility Scale 
•  Functional Independence Measure
•   Functional Reach Test/Modified Functional 
Reach Test
•  Functional Self-assessment
•  Functional Status Examination
•  Goal Attainment Scale, 
•  Hauser Ambulation Index
•  High-level Mobility Assessment Tool (HiMAT)
•   Impact of Participation and Autonomy 
Questionnaire (IPAQ) 
•  Jebsen Taylor Arm Function Test
•  Life Satisfaction Questionnaire (LISAT-9)
•  Modified Rankin Scale
•  Motor Activity Log
•  Motricity Index 
•  Participation Measure for Post-acute Care
•  Participation Objective, Participation Subjective
•  Participation Survey of Mobility Limited People
•   Physical Performance Battery for Patients with 
Cancer 
•  Reintegration to Normal Living/Life Index 
•  Six Minute Arm Test (6-MAT)
•  Short Performance Physical Battery
•  Timed 25 Foot Walk
•  Timed Up & Go (Cognitive and Manual) 
•  Wolf Motor Function Scale
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